Evidence map›Paper›PMID 42701139›Full record

ArticleInternational journal of clinical oncology2026

Gastrointestinal perforation associated with bevacizumab and palliative radiotherapy.

Kenji Makita, Masaki Nakamura, Yuichi Hiroshima, Hidenari Hirata, Masashi Wakabayashi, Saori Mishima, Akihito Kawazoe, Satoshi Saito, Sadamoto Zenda

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kenji MakitaDepartment of Radiation Oncology, National Cancer Center Japan Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan. kemaki3@east.ncc.go.jp.ORCID http://orcid.org/0000-0002-2219-6708
Masaki NakamuraDepartment of Radiation Oncology, National Cancer Center Japan Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan.
Yuichi HiroshimaDepartment of Radiation Oncology, National Cancer Center Japan Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan.
Hidenari HirataDepartment of Radiation Oncology, National Cancer Center Japan Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan.
Masashi WakabayashiBiostatistics Division, Center for Research Administration and Support, National Cancer Center Japan Hospital East, Kashiwa, Chiba, Japan.
Saori MishimaDepartment of Gastrointestinal Oncology, National Cancer Center Japan Hospital East, Kashiwa, Chiba, Japan.
Akihito KawazoeDepartment of Gastrointestinal Oncology, National Cancer Center Japan Hospital East, Kashiwa, Chiba, Japan.
Satoshi SaitoDepartment of Radiation Oncology, National Cancer Center Japan Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan.
Sadamoto ZendaDepartment of Radiation Oncology, National Cancer Center Japan Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe risk of gastrointestinal (GI) perforation associated with bevacizumab (Bev) in patients undergoing palliative radiotherapy (RT) remains unclear. This study investigated the incidence of GI perforation in colorectal cancer patients treated with Bev and palliative RT.

methodsWe retrospectively reviewed colorectal cancer patients who received Bev and palliative RT involving the GI tract between January 2013 and December 2025. Bev and palliative RT were defined as treatment with Bev within 4 weeks before RT initiation or within 4 weeks after RT completion.

resultsA total of 109 patients were analyzed. Bev was administered before RT in 44 patients (40.4%), after RT in 34 (31.2%), and both before and after RT in 31 (28.4%). The most common RT regimen was 8 Gy in a single fraction (38.5%), followed by 20 Gy in 5 fractions (37.6%) and 30 Gy in 10 fractions (21.1%). The median follow-up from RT initiation was 223 days. GI perforation occurred in 3 patients (2.8%; 95% confidence interval [CI], 0.6-7.8%), with a 180-day cumulative incidence of 2.1% (95% CI, 0.4-6.6%). All perforations occurred in the rectum within the RT field; two occurred within the planning target volume and one outside it. Compromised GI wall within the RT field was significantly associated with GI perforation (p = 0.010).

conclusionThe incidence of GI perforation was low in colorectal cancer patients treated with Bev and palliative RT. However, caution is warranted when compromised GI wall is present within the RT field.

Indexed as

BevacizumabGastrointestinalPalliativePerforationRadiotherapy

Identifiers

PMID42701139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.